Clearmind Medicine Announces Institutional Review Board Approval For FDA Clinical Trial Of CMND-100 At Second Clinical Site In Alcohol Use Disorder
Portfolio Pulse from Benzinga Newsdesk
Clearmind Medicine has received Institutional Review Board approval for its FDA clinical trial of CMND-100 at a second clinical site, focusing on treating alcohol use disorder.
October 10, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Clearmind Medicine has obtained IRB approval for its FDA clinical trial of CMND-100 at a second site, which is a significant step in its development for treating alcohol use disorder.
The IRB approval for a second clinical site is a positive development for Clearmind Medicine, as it indicates progress in the clinical trial process for CMND-100. This could lead to increased investor confidence and potential stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100